Caribou Biosciences Inc (CRBU) 13F Positioning & Ownership Changes (Q2 2026)

CRBU ranks #3871 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

CRBU is a disclosed holding of Jim Simons (Renaissance Technologies), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

138 institutions disclose a position in CRBU, but none treat it as a major bet — even Pfizer Inc, its most concentrated holder, allocates just 4.6% of its own portfolio to it.

BlackRock has added to its CRBU position for two straight quarters, increasing it by $10.4M to reach $13.8M today.

Ken Griffin has trimmed its CRBU position for two straight quarters, cutting it by $629.3K while still holding $348.2K.

CRBU is up 3.2% today, and institutions have been net buyers of $22.7M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

CRBU reported a net loss of $103.4M over the trailing twelve months.

• Not yet profitable — net loss of $103.4M over the trailing twelve months
• Revenue grew 10.0% year over year
• Net income improved year over year, from -$164.3M to -$103.4M
• Operating cash flow was negative, using $111.0M in cash
• Current ratio of 5.71x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.44x equity — within a conventional range